Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD

Status unconfirmed · Phase 4

Conditions studied: Chronic Kidney Diseases, Acute Coronary Syndrome

In brief

To compare clinical outcomes in patients with chronic kidney disease (CKD) presenting with an acute coronary syndrome (ACS) treated with clopidogrel or ticagrelor (both FDA approved and guideline indicated drugs for treating these patients upstream managed medically or with coronary revascularization).

Key facts

Study ID

NCT03150667

Run by

North Texas Veterans Healthcare System

People needed

220

Starts

2017-04-10

Expected to finish

2020-04-30

Last updated by the study team

2018-05-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hospital admission with non-emergent ACS qualifying diagnosis: chest pain, unstable angina or NSTEMI
• A decision to prescribe clopidogrel or ticagrelor in addition to aspirin (DAPT-dual antiplatelet therapy) by the attending physician
• A eGFR< 60 mL/min per 1.73 m.2 (as defined in the EMR or CPRS reported results)

You may not qualify if…

• Diagnosis of ST Elevation Myocardial Infarction (STEMI) at admission
• History of intra-cranial hemorrhage
• Bleeding requiring hospitalization, surgery, or transfusion within the past 3 months
• Life expectancy in the opinion of the provider < 6 months
• Chronic antithrombotic therapy
• Known allergy to clopidogrel or ticagrelor
• Patients on hemodialysis

Where it is running

• Durham VA Medical Center — Durham, North Carolina, United States (enrolling)
• VA North Texas Health Care System — Dallas, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.